The CIMAC-CIDC Network is an NCI Cancer Moonshot initiative that provides cutting-edge technology and expertise in genomic, proteomic, and functional molecular analysis to enhance clinical trials in cancer immune therapies.

Cancer Immune Monitoring and Analysis Centers (CIMACs)

The four Cancer Immune Monitoring and Analysis Centers (CIMACs), at Dana-Farber Cancer Institute, Stanford University, MD Anderson, and Mount Sinai, will be responsible for providing a wide range of state-of-the-art analyses for genomic, phenotypic and functional characterization of responses of patients in early phase clinical trials using analytically-validated and standardized platforms.

Cancer Immunologic Data Commons (CIDC)

The Cancer Immunologic Data Commons (CIDC), hosted by Dana-Farber Cancer Institute, will serve the bioinformatics needs of the network, optimization of data collection methodologies suitable for immune-related biomarkers, data integration and building a biomarker database for the secondary use by the large immuno-oncology community.

The CIMAC-CIDC network does not provide medical treatment or enroll patients in clinical trials. If you are a patient seeking cancer care, please contact a healthcare provider to discuss treatment options.